ES-015

N/A

Report date: 2025/06/11 14:31:02
First In Class

Base Information

Drug NameES-015
Drug Alias NameES-015ES-015-2
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionNKG2-C type II integral membrane protein agonistsNK cell lectin-like receptor subfamily C member 1 antagonists
TargetsNKG2-C type II integral membrane proteinNK cell lectin-like receptor subfamily C member 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesElpiscience (Shanghai) Biopharma Ltd
China Registration ClassN/A

Develop Information

Active CompaniesElpiscience (Shanghai) Biopharma Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A